title: Use of antineoplastic agents in patients with cancer who have HIV/AIDS.
abstract: Highly active antiretroviral therapy (HAART) has substantially reduced morbidity and mortality of AIDS-related complications in patients with HIV; however, the prevalence of AIDS-defining cancers and non-AIDS-defining cancers has increased. In this Review we discuss the management of HAART pharmacotherapy in relation to cytotoxic chemotherapy or targeted antineoplastic agents. We will review potential pharmacological interactions between antiretroviral and antineoplastic therapies and consider how to combine antiretroviral and antineoplastic agents in patients with HIV who are receiving HAART therapy.
authors.affiliation: Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA. mrudek2@jhmi.edu
authors.forename: Michelle A
authors.initials: MA
authors.lastname: Rudek
authors.forename: Charles
authors.initials: C
authors.lastname: Flexner
authors.forename: Richard F
authors.initials: RF
authors.lastname: Ambinder
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000188:drug therapy*; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D004347:Drug Interactions; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy*; D018570:Risk Assessment; D012307:Risk Factors
chemical_list: D019380:Anti-HIV Agents; D000970:Antineoplastic Agents